ARAYAccuray Incorporated shows mixed signals, with some fundamental strengths in its niche but facing profitability challenges and a competitive landscape. Technicals are mixed, suggesting a 'Hold' recommendation for now.
Accuray operates in the medical device sector, focusing on radiation therapy and radiosurgery. Demand is driven by an aging global population and increased cancer diagnoses, but competition and technological disruption are key considerations.
Accuray exhibits a mixed financial profile, with revenue growth over the past few years but persistent net losses and negative free cash flow in some periods. Its balance sheet shows manageable debt levels.
Accuray's stock price has shown some positive momentum recently, trading above key moving averages. However, oscillators are mixed, suggesting potential for consolidation.
| Factor | Score |
|---|---|
| Healthcare Demand Growth | 75 |
| Technological Advancement | 70 |
| Competition | 50 |
| Regulatory Environment | 65 |
| Healthcare Spending Trends | 40 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 30 |
| Growth | 45 |
| Balance Sheet Health | 40 |
| Cash Flow | 35 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
Positive EPS Surprise
Accuray Incorporated (ARAY) has demonstrated positive earnings per share (EPS) surprises in recent quarters, with the latest quarter (2025 Q1) reporting an EPS of $0.02 against an estimate of -$0.02, a surprise of 180.0%.
Improving Cash Position
The company's cash and cash equivalents have shown an increasing trend, from $88.74 million in Q2 2022 to $68.57 million in Q2 2024, with positive operating cash flow in some recent periods indicating cash generation capability.
Negative Net Income and Margins
Accuray Incorporated has consistently reported negative net income and net margins across the observed annual and quarterly periods, indicating ongoing unprofitability. For example, in 2024 Q2, the net income was -$15.55 million with a net margin of -3.5%.
High Debt Relative to Cash
The company's debt level (e.g., $210.75 million in Q2 2024) is significantly higher than its cash and cash equivalents ($68.57 million in Q2 2024), and its free cash flow has been negative in Q2 2024 (-$15.51 million), raising concerns about debt servicing capability.
August 2025
14
Next Earnings Date
H: $0.03
A: $0.01
L: $0.00
H: 125.10M
A: 124.47M
L: 123.80M
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
5.17 USD
The 39 analysts offering 1 year price forecasts for ARAY have a max estimate of 7.00 and a min estimate of 4.00.